Duvelisib - CAS 1201438-56-3
Catalog number: B0084-462545
Category: Inhibitor
Not Intended for Therapeutic Use. For research use only.
COA:
Inquire
Targets:
PI3K
Description:
Duvelisib, also known as IPI-145 and INK-1197, is an orally bioavailable, highly selective and potent small molecule inhibitor of the delta and gamma isoforms of phosphoinositide-3 kinase (PI3K) with potential immunomodulating and antineoplastic activities. Upon administration, PI3K delta/gamma inhibitor IPI 145 prevents the activation of the PI3K delta/gamma-mediated signaling pathways which may lead to a reduction in cellular proliferation in PI3K delta/gamma-expressing tumor cells. Unlike other isoforms of PI3K, the delta and gamma isoforms are overexpressed primarily in hematologic malignancies and inflammatory and autoimmune diseases. By selectively targeting these PI3K isoforms, PI3K signaling in normal, non-neoplastic cells is minimally or not affected which would result in a more favorable side effect profile.
Ordering Information
Catalog Number Size Price Stock Quantity
B0084-462545 100 mg $228 In stock
Bulk Inquiry
Publictions citing BOC Sciences Products
  • >> More
Appearance:
white solid powder
Synonyms:
IPI145; IPI 145; IPI-145. INK-1197; INK 1197; INK1197; Duvelisib.
MSDS:
Inquire
Application:
For research used only
Current Developer:
Infinity Pharmaceuticals, Inc. and Intellikine
1.The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL.
Balakrishnan K1,2, Peluso M3, Fu M2, Rosin NY2, Burger JA2, Wierda WG2, Keating MJ2, Faia K3, O'Brien S2, Kutok JL3, Gandhi V1,2. Leukemia. 2015 Sep;29(9):1811-22. doi: 10.1038/leu.2015.105. Epub 2015 Apr 28.
The functional relevance of the B-cell receptor (BCR) and the evolution of protein kinases as therapeutic targets have recently shifted the paradigm for treatment of B-cell malignancies. Inhibition of p110δ with idelalisib has shown clinical activity in chronic lymphocytic leukemia (CLL). The dynamic interplay of isoforms p110δ and p110γ in leukocytes support the hypothesis that dual blockade may provide a therapeutic benefit. IPI-145, an oral inhibitor of p110δ and p110γ isoforms, sensitizes BCR-stimulated and/or stromal co-cultured primary CLL cells to apoptosis (median 20%, n=57; P<0.0001) including samples with poor prognostic markers, unmutated IgVH (n=28) and prior treatment (n=15; P<0.0001). IPI-145 potently inhibits the CD40L/IL-2/IL-10 induced proliferation of CLL cells with an IC50 in sub-nanomolar range. A corresponding dose-responsive inhibition of pAKT(Ser473) is observed with an IC50 of 0.36 nM. IPI-145 diminishes the BCR-induced chemokines CCL3 and CCL4 secretion to 17% and 37%, respectively.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related PI3K Products


CAS 475110-96-4 ZSTK474

ZSTK474
(CAS: 475110-96-4)

ZSTK474 is a novel phosphatidylinositol 3-kinase (PI3K) inhibitor, which strongly inhibits cancer cell proliferation. Phosphoinositide 3-kinase (PI3K) is a pote...

CAS 1201438-56-3 Duvelisib

Duvelisib
(CAS: 1201438-56-3)

Duvelisib, also known as IPI-145 and INK-1197, is an orally bioavailable, highly selective and potent small molecule inhibitor of the delta and gamma isoforms o...

CAS 1349796-36-6 XL-765, SAR245409,

XL-765, SAR245409,
(CAS: 1349796-36-6)

CAS 371242-69-2 IC-87114

IC-87114
(CAS: 371242-69-2)

CAS 648450-29-7 AS-605240

AS-605240
(CAS: 648450-29-7)

AS605240 is a selective PI3Kgamma inhibitor, has been proved effective on several inflammatory diseases. Orally administration of AS605240 significantly prevent...

CAS 371935-79-4 PI-103 Hydrochloride

PI-103 Hydrochloride
(CAS: 371935-79-4)

A selective class I PI3K inhibitor; it inhibits PI3K p110 isoforms, mTOC1 and also DNA-PK; a valuable tool compound

GDC-0084
(CAS: 1382979-44-3)

GDC-0084, a PI3K inhibitor, has been found to have probable antineoplastic effect and could pass blood-brain barrier with favourable penetration. It was just li...

PI3Kα inhibitor 1
(CAS: 1235449-52-1)

PI3Kα inhibitor 1 is an inhibitor of PI3Kα as well as HDAC and probably have antineoplastic activity. IC50: <0.1 μM.

CAS 1172118-03-4 PI3Ky inhibitor 1

PI3Ky inhibitor 1
(CAS: 1172118-03-4)

PI3Ky inhibitor 1 is a potent PI3Ky inhibitor.

CAS 957054-33-0 GDC-0941 dimethanesulfonate

GDC-0941 dimethanesulfonate
(CAS: 957054-33-0)

GDC-0941 dimethanesulfonate is a potent inhibitor of PI3Kα/δ with modest selectivity against p110β and p110γ. It is a novel selective class I phosphatidylinosit...

CAS 1245537-68-1 BGT226 (NVP-BGT226)

BGT226 (NVP-BGT226)
(CAS: 1245537-68-1)

BGT226 (NVP-BGT226) is a novel class I PI3K/mTOR inhibitor for PI3Kα/β/γ with IC50 of 4 nM/63 nM/38 nM. Phase 1/2.

CAS 1312445-63-8 NVP-BKM120 Hydrochloride

NVP-BKM120 Hydrochloride
(CAS: 1312445-63-8)

NVP-BKM120 Hcl(BKM120) is a selective PI3K inhibitor of p110&alpha;/&beta;/&delta;/&gamma; with IC50 of 52 nM/166 nM/116 nM/262 nM, respectively.

Duvelisib R enantiomer
(CAS: 1261590-48-0)

The R isomer analogue of Duvelisib which is a high selective PI3K δ/γ inhibitor.

CAS 1383716-40-2 Vps34-PIK-III

Vps34-PIK-III
(CAS: 1383716-40-2)

Vps34-PIK-III is a potent and selective inhibitor of the type 3 phosphatidylinositol 3-kinase (PI3K) vacuolar protein sorting 34 (Vps34) (IC50= 18 nM). Vps34-PI...

CAS 1254036-66-2 GSK2292767

GSK2292767
(CAS: 1254036-66-2)

GSK2292767 is a Phosphatidylinositol 3 kinase delta inhibitor applicated for the treatment of respiratory diseases including asthma and COPD in clinical trials....

CAS 593960-11-3 PIK-93

PIK-93
(CAS: 593960-11-3)

PIK-93 is a potent PI3K inhibitor.

CAS 1627494-13-6 AZD8186

AZD8186
(CAS: 1627494-13-6)

AZD 8186 is a selective PI3Kβ/δ inhibitor (IC50= 0.003 μM for PI3Kβ, and 0.017 μM for PI3Kδ) with potential antineoplastic activity. It shows no significant bin...

CAS 1246535-95-4 Desmethyl-VS-5584

Desmethyl-VS-5584
(CAS: 1246535-95-4)

Desmethyl-VS-5584, a demethyl analogue of VS-5584, is a PI3K/mTOR kinase inhibitor for the treatment of cancer.

CAS 1007207-67-1 CH5132799

CH5132799
(CAS: 1007207-67-1)

CH5132799 is a novel class I PI3K inhibitor, which exhibited a strong inhibitory activity especially against PI3K; (IC(50)=0.014 uM). In human tumor cell lines ...

CAS 677297-51-7 TG100-115

TG100-115
(CAS: 677297-51-7)

TG100-115, inhibited PI3K γ and -δ(IC50 values of 83 and 235 nM, respectively), whereas both PI3Kα and -β were relatively unaffected (IC50 values>1 μM). As a ga...

Chemical Structure

CAS 1201438-56-3 Duvelisib

Quick Inquiry

Verification code

Featured Items